Subsaturated transdermal drug delivery device exhibiting enhanced drug flux

Patent 5164190 Issued on November 17, 1992. Estimated Expiration Date:

December 11, 2010. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

Skin permeation enhancer compositions
Patent #: 4568343
Issued on: 02/04/1986
Inventor: Leeper , et al.

Transdermal delivery of highly ionized fat insoluble drugs
Patent #: 4645502
Issued on: 02/24/1987
Inventor: Gale , et al.

Transdermal contraceptive formulations
Patent #: 4816258
Issued on: 03/28/1989
Inventor: Nedberge , et al.

Device for administering an active agent to the skin or mucosa
Patent #: 4849224
Issued on: 07/18/1989
Inventor: Chang , et al.

Skin permeation enhancer compositions using glycerol monooleate
Patent #: 4863738
Issued on: 09/05/1989
Inventor: Taskovich

Skin permeation enhancer compositions using sucrose esters
Patent #: 4865848
Issued on: 09/12/1989
Inventor: Cheng , et al.

Transdermal drug delivery device
Patent #: 4867982
Issued on: 09/19/1989
Inventor: Campbell , et al.

Skin permeation enhancer compositions using sucrose esters
Patent #: 4900555
Issued on: 02/13/1990
Inventor: Cheng, et al.

Transdermal delivery of drugs from an aqueous reservoir
Patent #: 4904475
Issued on: 02/27/1990
Inventor: Gale, et al.

Subsaturated transdermal therapeutic system having improved release characteristics
Patent #: 4908027
Issued on: 03/13/1990
Inventor: Enscore, et al.

More ...

Inventors

Assignee

Theratech, Inc.

Application

No. 626685 filed on 12/11/1990

US Classes:

424/448, Pressure sensitive adhesive means424/449Transdermal or percutaneous

Examiners

Primary: Page, Thurman K.
Assistant: Horne, Leon R.

Attorney, Agent or Firm

Morrison & Foerster

International Class

A61F 013/02

Abstract

Transdermal administration of hydrophobic drugs via a diffusion mechanism in which the drug is dissolved in a carrier at concentrations that are 20% to 80% of the saturation concentration. The flux of drug from the device is non-Fickian and is substantially greater than the flux observed when the drug is at saturation.